These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Lamivudine plus tenofovir versus lamivudine plus adefovir for the treatment of hepatitis B virus in HIV-coinfected patients, starting antiretroviral therapy. Sarkar J, Saha D, Bandyopadhyay B, Saha B, Chakravarty R, Guha SK. Indian J Med Microbiol; 2018; 36(2):217-223. PubMed ID: 30084414 [Abstract] [Full Text] [Related]
14. Effects of long-term tenofovir-based combination antiretroviral therapy in HIV-hepatitis B virus coinfection on persistent hepatitis B virus viremia and the role of hepatitis B virus quasispecies diversity. Audsley J, Bent SJ, Littlejohn M, Avihingsanon A, Matthews G, Bowden S, Bayliss J, Luciani F, Yuen L, Fairley CK, Locarnini S, Lewin SR, Sasadeusz J. AIDS; 2016 Jun 19; 30(10):1597-606. PubMed ID: 26950313 [Abstract] [Full Text] [Related]
15. Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients. Kosi L, Reiberger T, Payer BA, Grabmeier-Pfistershammer K, Strassl R, Rieger A, Peck-Radosavljevic M. J Viral Hepat; 2012 Nov 19; 19(11):801-10. PubMed ID: 23043387 [Abstract] [Full Text] [Related]
19. Hepatitis B virus coinfection is associated with high early mortality in HIV-infected Tanzanians on antiretroviral therapy. Christian B, Fabian E, Macha I, Mpangala S, Thio CL, Ulenga N, Mugusi F, Ammerman LR, Fawzi W, Green R, Murphy R, Hawkins C. AIDS; 2019 Mar 01; 33(3):465-473. PubMed ID: 30702515 [Abstract] [Full Text] [Related]